Bio-Techne is set to announce its third-quarter earnings next month, and Wall Street expects the company’s EPS to decrease by ...

Bio-Techne Corporation, a global provider of life science research tools, analytical instruments, and diagnostics, today ...

What Happened? A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a ...

The DCF model implemented in this article suggests that Bio-Techne is overvalued by 34.53%. Bio-Techne has allocated significant financial resources to capex. Due to these resources, its revenues ...

Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026 Steve Crouse, Senior Vice President of Bio-Techne's Analytical Solutions ...

Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports ...

Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 6, 2026, at 8:00 a.m. CDT to review its third quarter fiscal 2026 ...

Bio-Techne is a leading provider of specialized reagents, analytical instruments, and diagnostic solutions for the life sciences and clinical diagnostics sectors. The company leverages a diverse ...

Baron Funds, an investment management company, released its “Baron Asset Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. stocks rose amid volatility caused ...

Bio-Techne introduces a streamlined brand architecture that organizes its technologies into three focused portfolio brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics.The new ...